DM
SGMO

Deerfield Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Deerfield Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-653,000
Closed -$9.79M – 103
2017
Q3 		$9.79M Sell
653,000
-441,305
-40% -$4.88M 0.44% 64
2017
Q2 		$9.63M Buy
1,094,305
+256,342
+31% +$1.64M 0.51% 57
2017
Q1 		$4.36M Hold
837,963
– – 0.17% 87
2016
Q4 		$2.56M Buy
+837,963
New +$3.05M 0.11% 85
2014
Q4 		– Sell
-50,000
Closed -$539K – 128
2014
Q3 		$539K Buy
+50,000
New +$653K 0.02% 127

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Deerfield Management's SGMO Position: Q4 2017 in Review

Deerfield Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2017, closing a stake of 653,000 shares — an estimated $9.79M sold.

Deerfield Management first reported a position in SGMO in Q3 2014 and held it in 5 quarters. The position peaked at $9.79M in Q3 2017. 170 funds tracked by Wall St. Rank hold SGMO as of Q4 2017.

  • Deerfield Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2017 after selling out during the quarter.
  • Deerfield Management sold 653,000 SANGAMO THERAPEUTICS INC shares in Q4 2017, an estimated $9.79M.
  • Deerfield Management first reported a position in SANGAMO THERAPEUTICS INC in Q3 2014 and held it in 5 quarters.
  • Deerfield Management's SANGAMO THERAPEUTICS INC position peaked at $9.79M in Q3 2017.
  • 170 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2017.

Based on Deerfield Management's 13F filing for Q4 2017, filed 14 Feb 2018.